Wolfe Research Downgrades Boston Scientific Corporation (BSX) To Peer Perform
Key takeaways
- On May 29, Wolfe Research downgraded the stock from Outperform to Peer Perform.
- This marks the end of the firm’s bullish outlook on the stock for four years, with the adjustment coming after the company said sales growth of its Watchman implant, which reduces the risk of stroke, was slowing.
- Following the Watchman update, TD Cowen also lowered its price target on the stock to $61 from $80, but maintained a Buy rating.
Wolfe Research Downgrades Boston Scientific Corporation (BSX) To Peer Perform Ashar Jawad Mon, June 1, 2026 at 9:14 PM GMT+7 1 min read BSX ^GSPC Boston Scientific Corporation (NYSE:BSX) is among the 10 Most Oversold S&P 500 Stocks So Far in 2026. On May 29, Wolfe Research downgraded the stock from Outperform to Peer Perform.
This marks the end of the firm’s bullish outlook on the stock for four years, with the adjustment coming after the company said sales growth of its Watchman implant, which reduces the risk of stroke, was slowing.
Wolfe Research now anticipates 7% organic growth for Boston Scientific Corporation (NYSE:BSX) in 2027, according to TipRanks, which would put the share price in the early $50s, roughly the same level the stock is trading at currently.